Brooks Gabriel 4

What Happened

• Dr. Brooks Gabriel, Chief Medical Officer of Solid Biosciences (SLDB), had 10,937 restricted stock units (RSUs) convert into common shares on Feb 13, 2026. These were RSU vesting/convertible-derivative transactions (reported as "M" — exercise/conversion of derivative).
• Following the vesting, a sell-to-cover transaction to satisfy withholding taxes was executed (reported with a weighted average sale price of $5.82, range $5.23–$6.14). The filing indicates the sell-to-cover was automatic under a previously adopted instruction and not a discretionary trade.

Key Details

• Transaction dates: RSU conversion — Feb 13, 2026; sell-to-cover execution — Feb 18, 2026.
• Shares converted: 10,937 RSUs converted into 10,937 common shares (acquired via conversion).
• Sale details: weighted average sale price reported $5.82; price range $5.23–$6.14. The filing notes the sale was to cover tax withholding under a durable automatic sales instruction (sell-to-cover).
• Footnotes: F1 explains each RSU equals a contingent right to one common share; F2 confirms the sale was to cover withholding taxes and not a discretionary trade; F4 notes the RSUs were granted 2/13/2024 and vest 25% each anniversary for four years.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: Form filed Feb 18, 2026 for transactions on Feb 13, 2026 — appears to be timely (within SEC Form 4 reporting window).

Context

• This was a routine vesting of previously granted RSUs with an automatic sell-to-cover for taxes. Such sell-to-cover transactions are common and reflect tax withholding, not necessarily a discretionary sell signal by the insider.
• The conversion of RSUs is not a market purchase; it’s the issuance of shares upon vesting.